Program
BI 1584862
A development code. Also written as “[13C]-labeled BI 1584862”.
In Boehringer Ingelheim's pipeline, Phospholipid modulator
. Its studies are mostly in Geographic Atrophy · Hepatic Insufficiency, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 71 open or running | phase 2since Jan 7, 2025 | Aug 29, 2022 | Dec 22, 2026phase 2 · NCT06769048 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 1584862
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2022First study: phase 1 study in HealthyFirst studyNCT05520827 · 77 enrolled · Germany
- Aug 17, 2023Phase 1 study in HealthyNCT06006598 · 50 enrolled · Germany
- Sep 12, 2023Phase 1 study in HealthyNCT06041438 · 14 enrolled · Germany
- Nov 20, 2023Phase 1 study in HealthyNCT06148948 · 32 enrolled · Japan
- Jan 7, 2025Phase 2 study in Geographic AtrophyNCT06769048 · 150 enrolled · United States, Puerto Rico
- May 2, 2025Phase 1 study in Hepatic InsufficiencyNCT06957756 · 43 enrolled · United States
- Jan 2, 2026Phase 1 study in HealthyNCT07336758 · 8 enrolled · Netherlands
Ahead
- Dec 22, 2026Primary completion: phase 2 study in Geographic AtrophyNCT06769048
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Phospholipid modulator”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07336758Healthy · Netherlands | 1 | Completed | Mar 4, 2026 | 8 |
| NCT06957756Hepatic Insufficiency · United States | 1 | Completed | May 21, 2026 | 43 |
| NCT06769048Geographic Atrophy · United States, Puerto Rico | 2 | Active, not recruiting | Dec 22, 2026 | 150 |
| NCT06148948Healthy · Japan | 1 | Completed | May 21, 2024 | 32 |
| NCT06041438Healthy · Germany | 1 | Completed | Nov 10, 2023 | 14 |
| NCT06006598Healthy · Germany | 1 | Completed | May 5, 2024 | 50 |
| NCT05520827Healthy · Germany | 1 | Completed | Mar 6, 2023 | 77 |
How it is read
Names in the registry
- “BI 1584862”, 6 entries
- “[13C]-labeled BI 1584862”, 1 entry
Codes read as this program: BI1584862.
Conditions, from the studies’ own filings
- Geographic Atrophy, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.